Research on MOTS-c for insulin resistance is promising but early. Mouse studies show strong effects on insulin sensitivity, while human data are limited and mixed. TelosRX breaks down what each study actually found, and what it didn't.
MOTS-c is a tiny peptide your mitochondria make on their own. It's only 16 amino acids long. Yet it has become one of the most talked-about molecules in metabolic research.
The reason is simple. Early lab work suggested it helps muscle handle glucose. That's the core problem in insulin resistance. Below, we walk through the key studies on MOTS-c for insulin resistance, one finding at a time.
A quick ground rule first. MOTS-c is not FDA-approved for any use. Everything here is research evidence, not a promise of results.
What Is MOTS-c, in Plain Terms?
MOTS-c stands for "mitochondrial open reading frame of the 12S rRNA type-c." In plain English: a peptide coded by mitochondrial DNA, not the DNA in your cell's nucleus.
That makes it part of a small family called mitochondrial-derived peptides. Humanin is its better-known cousin. Our explainer on mitochondrial-derived peptides covers the whole group.
- Where it acts: mainly skeletal muscle, the body's largest glucose sink.
- Proposed pathway: AMPK (an energy-sensing enzyme) and related metabolic signals.
- Why it matters here: muscle that ignores insulin is a hallmark of insulin resistance.
Why Researchers Link MOTS-c and Insulin Resistance
Insulin resistance means cells respond poorly to insulin. Blood sugar stays higher, and the pancreas pushes out more insulin to compensate.
Muscle clears most glucose after a meal. So anything that helps muscle respond to insulin draws attention. MOTS-c showed up in early studies as a possible muscle-level signal.
That's the hypothesis. Here's what the evidence says so far.
Finding 1: The 2015 Mouse Study That Started It All
The first major paper appeared in Cell Metabolism in 2015. Researchers at the University of Southern California identified MOTS-c and tested it in mice.
In that preclinical research, MOTS-c treatment blocked both age-related and high-fat-diet-related insulin resistance in mice. It also limited diet-induced weight gain. Muscle appeared to be the main target tissue.
- Model: mice and cell cultures.
- Key signal: improved insulin sensitivity and glucose handling.
- Proposed mechanism: AMPK activation through the folate cycle and AICAR buildup.
The limits are just as important. Mice are not people. Doses, timing, and metabolism differ a lot between species.
Finding 2: Exercise Raises MOTS-c in Human Muscle
A 2021 study in Nature Communications took the research into people, at least partly. It found that exercise raised MOTS-c levels in human skeletal muscle and blood.
The authors reported muscle MOTS-c rose about 11.9-fold after exercise. Plasma levels rose roughly 50% during and after the session. Levels stayed elevated after a four-hour rest.
The same paper tested MOTS-c in mice of different ages. Treated older mice showed better physical capacity. Some treated mice on a high-fat diet also gained less weight.
- Human part: small group, measured natural MOTS-c response to exercise.
- Mouse part: tested injected MOTS-c on physical performance.
- Takeaway: MOTS-c may be one of the signals linking exercise to metabolic health.
Note what this study did not test. It didn't give MOTS-c to humans and measure insulin resistance. Our deep dive on the "exercise mimetic" idea covers that gap.
Finding 3: Human Blood Levels Tell a Mixed Story
If MOTS-c helps insulin sensitivity, you might expect lower levels in people with insulin resistance. Human data don't line up neatly.
Some earlier studies reported lower circulating MOTS-c in certain groups with obesity. But a 2025 cross-sectional study of 85 adults in Archives of Endocrinology and Metabolism found something different. Serum MOTS-c correlated positively with HOMA-IR, a common insulin resistance score.
The authors suggested MOTS-c may rise as a compensatory response. They also noted a cross-sectional study can't prove cause and effect.
- Age appeared to matter. Older age linked to lower MOTS-c.
- Obesity alone didn't clearly change levels in that cohort.
- Bottom line: blood MOTS-c is not a validated test for insulin resistance.
Finding 4: An Early Human Trial of a MOTS-c Analog
A drug company tested a modified MOTS-c analog called CB4211 in a small Phase 1a/1b study. The 2021 results came from a company announcement, not a peer-reviewed paper.
The company reported a modest drop in blood glucose versus placebo over four weeks. Liver fat fell in both the drug and placebo groups by similar amounts. The trial was very small, with about 20 participants in the key portion.
So this is a weak signal at best. It's also an analog, not native MOTS-c. Read it as a hint, not a result.
Finding 5: A Placebo-Controlled Phase 2a Trial Is Underway
The most relevant human study is still running. A Phase 2a trial registered as NCT07505745 on ClinicalTrials.gov is testing MOTS-c in adults with prediabetes and overweight or obesity.
- Design: randomized, double-blind, placebo-controlled.
- Size: about 120 participants.
- Duration: 12 weeks of daily dosing, with follow-up through week 16.
- Main measure: an insulin sensitivity index from a glucose tolerance test.
- Estimated primary completion: early 2027.
Until those results publish, there's no controlled human efficacy data for MOTS-c and insulin sensitivity.
The Evidence at a Glance
| Study | Model | What it measured | What it found | Evidence level |
|---|---|---|---|---|
| Lee et al., 2015, Cell Metabolism | Mice, cells | Insulin sensitivity, weight gain | Blocked diet- and age-related insulin resistance in mice | Preclinical |
| Reynolds et al., 2021, Nature Communications | Humans (exercise), mice | MOTS-c response to exercise; physical capacity | Exercise raised muscle and blood MOTS-c; treated mice performed better | Small human observation plus preclinical |
| 2025 cross-sectional study | 85 adults | Serum MOTS-c vs HOMA-IR | Positive correlation; may be compensatory | Observational |
| CB4211 Phase 1a/1b, 2021 | About 20 adults with obesity and fatty liver | Safety, glucose, liver fat | Modest glucose signal; liver fat similar to placebo | Early human, analog, company-reported |
| NCT07505745 Phase 2a | About 120 adults with prediabetes | Insulin sensitivity index | Results pending | Ongoing RCT |
What the Research Doesn't Show Yet
Honest gaps matter as much as findings. Here's what remains unknown:
- Whether injected MOTS-c improves insulin sensitivity in humans.
- What dose, if any, would be effective and well tolerated long term.
- How it compares to proven tools like exercise, weight loss, or metformin.
- Long-term safety data in people.
If you're curious how it stacks up against a well-studied drug, see our MOTS-c vs metformin comparison.
What This Means for You Right Now
The best-supported ways to improve insulin sensitivity are still the basics. Regular exercise, especially resistance training. Weight loss when appropriate. Better sleep. A diet built around protein, fiber, and minimally processed foods.
Interestingly, exercise itself raises your own MOTS-c. That's a nice bonus for the habit you should build anyway.
Curious whether a peptide protocol fits your goals? Learn how TelosRX approaches MOTS-c. Compounded MOTS-c is not FDA-approved. Any peptide therapy is subject to medical approval by a licensed provider and to current federal compounding rules, so availability can change.
TelosRX works asynchronously. You complete an online intake, and a licensed provider reviews it on their own schedule. There's no live video call required.
Frequently Asked Questions
Does MOTS-c improve insulin sensitivity in humans?
Not proven yet. The strongest evidence comes from mouse studies, where MOTS-c blocked diet- and age-related insulin resistance. Human data are limited to small observational studies and an early analog trial. A placebo-controlled Phase 2a trial in adults with prediabetes is underway, with results expected after its estimated 2027 completion date.
How does MOTS-c work on blood sugar?
Preclinical research suggests MOTS-c acts mainly in skeletal muscle. It appears to activate AMPK, an enzyme that senses cellular energy and helps muscle take up glucose. In mice, this was linked to better insulin sensitivity. Whether the same mechanism produces meaningful effects in people is still being studied.
Is MOTS-c FDA-approved?
No. MOTS-c is not FDA-approved for insulin resistance, diabetes, weight loss, or any other use. It remains investigational. Any compounded form is not FDA-approved, and whether a provider can prescribe it depends on a licensed provider's evaluation and current federal compounding regulations.
Does exercise increase MOTS-c naturally?
Yes, according to a 2021 study in Nature Communications. Researchers found MOTS-c in human skeletal muscle rose about 11.9-fold after exercise, and blood levels rose roughly 50%. Levels stayed elevated hours later. This suggests MOTS-c may be one of the signals linking physical activity to metabolic health.
Is MOTS-c the same as metformin?
No. Metformin is an FDA-approved diabetes medication with decades of human data. MOTS-c is an investigational peptide made by mitochondria. Both are linked to AMPK signaling, which is why they're often compared. But only metformin has proven, large-scale human evidence for blood sugar control.
What are the side effects of MOTS-c?
Human safety data are very limited. The small CB4211 analog trial reported the drug was generally well tolerated over four weeks, according to the company. That's not enough to define a side effect profile. Long-term safety in people is unknown, which is one reason any use requires a licensed provider's review.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.